Astellas dumps Theravance's MRSA drug Vibativ

Astellas Pharma parted ways with Theravance ($THRX), ending a promotional partnership on the infection-fighter Vibativ. FDA-approved in 2009, the drug targets infections caused by resistant staph bacteria. Theravance said it is looking for a new marketing partner and working on "re-establishing" consistent supplies of the product. Report

Suggested Articles

After a major label expansion in December, Amarin's Vascepa is preparing a major boom in sales with its marketing team nearly scaled up.

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

Data on Roche's Polivy aren't yet enough to win support from England's cost watchdogs, who rejected the medicine based on long-term…